Johnson & Johnson (UKEX:JNJ) E10: ₴193.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:JNJ Johnson & Johnson UKEX:JNJ
81 GF Score
Price ₴5,947.00
GF Value ₴4,410.94
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson E10?

Johnson & Johnson UKEX:JNJ 81 E10 is ₴193.66 as of Mar. 2026. GuruFocus rates UKEX:JNJ with a GF Score™ of 81/100 and a GF Value™ of ₴4,410.94. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Johnson & Johnson's adjusted earnings per share data for the three months ended in Mar. 2026 was ₴96.167. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₴193.66 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Johnson & Johnson's average E10 Growth Rate was 4.60% per year. During the past 3 years, the average E10 Growth Rate was 7.60% per year. During the past 5 years, the average E10 Growth Rate was 9.20% per year. During the past 10 years, the average E10 Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Johnson & Johnson was 15.60% per year. The lowest was -0.10% per year. And the median was 9.10% per year.

As of today (2026-07-14), Johnson & Johnson's current stock price is ₴5947.00. Johnson & Johnson's E10 for the quarter that ended in Mar. 2026 was ₴193.66. Johnson & Johnson's Shiller PE Ratio of today is 30.71.

During the past 13 years, the highest Shiller PE Ratio of Johnson & Johnson was 33.32. The lowest was 19.57. And the median was 26.87.


Johnson & Johnson  (UKEX:JNJ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Johnson & Johnson's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=5947.00/193.66
=30.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Johnson & Johnson was 33.32. The lowest was 19.57. And the median was 26.87.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Johnson & Johnson E10 Related Terms


Johnson & Johnson E10 Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson E10 Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 223.12 274.32 298.54 224.72

Johnson & Johnson Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 272.89 299.00 249.85 224.72 193.66

UKEX:JNJ vs ABBV, MRK, AMGN: E10 Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Shiller PE Ratio falls into.


UKEX:JNJ
81GF Score
Johnson & Johnson UKEX:JNJ
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Johnson & Johnson's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=96.167/330.2130*330.2130
=96.167

Current CPI (Mar. 2026) = 330.2130.

Johnson & Johnson Quarterly Data

per share eps CPI Adj_EPS
201606 64.261 241.018 88.042
201609 68.755 241.428 94.040
201612 62.014 241.432 84.818
201703 72.350 243.801 97.993
201706 62.913 244.955 84.810
201709 61.565 246.819 82.366
201712 -179.302 246.524 -240.171
201803 71.900 249.554 95.139
201806 65.160 251.989 85.387
201809 64.710 252.439 84.647
201812 50.330 251.233 66.152
201903 62.464 254.202 81.142
201906 93.471 256.143 120.500
201909 29.659 256.759 38.144
201912 67.407 256.974 86.618
202003 97.515 258.115 124.753
202006 61.115 257.797 78.282
202009 59.767 260.280 75.825
202012 29.210 260.474 37.031
202103 104.256 264.877 129.972
202106 105.604 271.696 128.349
202109 61.565 274.310 74.112
202112 79.540 278.802 94.207
202203 86.730 287.504 99.614
202206 80.888 296.311 90.143
202209 75.495 296.808 83.992
202212 59.767 296.797 66.496
202303 -1.348 301.836 -1.475
202306 88.078 305.109 95.325
202309 458.815 307.789 492.242
202312 75.046 306.746 80.787
202403 60.217 312.332 63.664
202406 86.730 314.175 91.157
202409 49.881 315.301 52.240
202412 63.362 315.605 66.295
202503 204.018 319.799 210.662
202506 102.908 322.561 105.349
202509 95.268 324.800 96.856
202512 94.369 324.054 96.163
202603 96.167 330.213 96.167

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₴193.66 mean?
Johnson & Johnson (UKEX:JNJ) has a E10 of ₴193.66 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's E10 too high?
Johnson & Johnson's current E10 is ₴193.66. Overall, Johnson & Johnson has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's E10 compare to ABBV and MRK?
Johnson & Johnson's E10 of ₴193.66 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current E10 is ₴193.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Johnson & Johnson (UKEX:JNJ) has a current E10 of ₴193.66. The stock's GF Value™ is ₴4,410.94, compared to a current price of ₴5,947.00 — trading 34.8% above its estimated fair value. The current E10 is ₴193.66. Johnson & Johnson's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Johnson & Johnson (UKEX:JNJ), the current E10 is ₴193.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (UKEX:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of ₴5,947.00 is trading 34.8% above its estimated GF Value™ of ₴4,410.94.

Key valuation signals for UKEX:JNJ:

  • E10: ₴193.66
  • GF Value™: ₴4,410.94 vs. price of ₴5,947.00 (34.8% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the UKEX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
81GF Score

Get the complete analysis for UKEX:JNJ

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴5,947.00
Price
₴4,410.94
GF Value